statistical analysis plan for stage 1 embarc (establishing moderators and biosignatures of antidepressant response for clinical care) study
Clicks: 242
ID: 225765
2017
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
242 views
35 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #16 of 32 articles by views in ingenierías usbmed
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Antidepressant medications are commonly used to treat depression, but only about 30% of patients reach remission with any single first-step antidepressant. If the first-step treatment fails, response and remission rates at subsequent steps are even more limited. The literature on biomarkers for treatment response is largely based on secondary analyses of studies designed to answer primary questions of efficacy, rather than on a planned systematic evaluation of biomarkers for treatment decision. The lack of evidence-based knowledge to guide treatment decisions for patients with depression has lead to the recognition that specially designed studies with the primary objective being to discover biosignatures for optimizing treatment decisions are necessary. Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) is one such discovery study. Stage 1 of EMBARC is a randomized placebo controlled clinical trial of 8 week duration. A wide array of patient characteristics is collected at baseline, including assessments of brain structure, function and connectivity along with electrophysiological, biological, behavioral and clinical features. This paper reports on the data analytic strategy for discovering biosignatures for treatment response based on Stage 1 of EMBARC.
| Reference Key |
petkova2017contemporarystatistical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Eva Petkova;R. Todd Ogden;Thaddeus Tarpey;Adam Ciarleglio;Bei Jiang;Zhe Su;Thomas Carmody;Philip Adams;Helena C. Kraemer;Bruce D. Grannemann;Maria A. Oquendo;Ramin Parsey;Myrna Weissman;Patrick J. McGrath;Maurizio Fava;Madhukar H. Trivedi |
| Journal | ingenierías usbmed |
| Year | 2017 |
| DOI |
10.1016/j.conctc.2017.02.007
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.